Clinical Research Directory
Browse clinical research sites, groups, and studies.
Clinical Follow-up Study of Rituximab in the Treatment of Nephrotic Syndrome in Children
Sponsor: The First Affiliated Hospital of Xiamen University
Summary
This was a retrospective study. Children who were diagnosed with refractory nephrotic syndrome and treated with rituximab (RTX) and followed up for ≥1 year in the Department of Pediatrics, the First Affiliated Hospital of Xiamen University from March 2020 to March 2026 were enrolled. Personal information, past medical history, clinical examination data and follow-up data before and after the use of RTX were extracted from the medical record system. (1) The median relapse-free survival, the number of relapses and the adverse reactions of RTX were compared before and after RTX treatment, and the clinical efficacy and safety of RTX were evaluated. (2) By comparing the annual relapse frequency, reduction and withdrawal of steroids and immunosuppressive agents, B cell reconstitution and adverse drug reactions between prophylactic RTX and post-relapse RTX maintenance regimens; (3) Multivariate analysis of risk factors for recurrence of nephropathy after RTX treatment. (4) growth indicators monitoring patient evaluation and RTX medical economic benefit analysis.
Key Details
Gender
All
Age Range
1 Year - 18 Years
Study Type
OBSERVATIONAL
Enrollment
50
Start Date
2020-03-01
Completion Date
2028-03-01
Last Updated
2024-07-31
Healthy Volunteers
No
Interventions
Rituximab
B lymphocyte reconstitution was performed regularly after the administration of rituximab, and 1-4 doses of rituximab were given according to the exhaustion of B cells in children.
Locations (1)
First affiliated hospital of xiamen university
Xiamen, Fujian, China